Daxor Corp (DXR)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$10.27-2.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Daxor is improving revenue from $11.9M in 2026 to $20.8M in 2027. Losses are shrinking with EPS improving from -$0.21 to -$0.03. The company has stable management and no recent negative news. Its valuation is slightly below peers, offering upside if turnaround succeeds.
Daxor remains unprofitable with negative free cash flow and high risk. Revenue growth is uncertain with only one analyst covering. The stock is volatile and the turnaround may stall or fail.
The price is about 6% above our fair value near $9.8, reflecting modest optimism. The market expects very low growth and continued losses, which matches the cautious outlook.
Breaks if: EPS remains below -$0.10 in FY27
Breaks if: FCF yield remains below -2% over next 4 quarters
Breaks if: revenue falls below $15M in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity within the healthcare sector. The current thesis state is characterized by low confidence due to recent erratic earnings surprises and a lack of financial performance history.
The market appears to have priced in a low level of fragility, indicating that there are no immediate concerns affecting DXR's stability. Valuation has significantly decreased, suggesting that expectations may have adjusted to reflect recent challenges.
Management is stable, but the high risk associated with the business could lead to volatile performance. Recent earnings surprises have been erratic, and while there is a low probability of missing earnings, the smaller-cap nature of DXR increases the risk of fluctuations.
The thesis hinges on the performance of sector bellwethers like ISRG, BDX, and RMD. Favorable earnings and guidance from these companies could boost DXR, while any signs of weakness could negatively impact its momentum.
In the next 1 to 3 years, DXR's performance will largely depend on broader healthcare sector trends and economic conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation fell by 54.0 points (from 70.0 to 16.0).
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.